Here, CRISPR-based dual-screening strategies (cell viability and protein stabilization) successfully identified USP32 as a novel and bona fide candidate that governs resistance for YM155 uptake by destabilizing SLC35F2 protein levels in a wide range of cancer cells. Here, USP32 is linked to cancer.